Sunil Badve
YOU?
Author Swipe
View article: A Thymus-Independent Artificial Organoid System Supports Complete Thymopoiesis from Rhesus Macaque-Derived Hematopoietic Stem and Progenitor Cells
A Thymus-Independent Artificial Organoid System Supports Complete Thymopoiesis from Rhesus Macaque-Derived Hematopoietic Stem and Progenitor Cells Open
Background: T cell regeneration in the thymus is intrinsically linked to the T cell-biased lineage differentiation of hematopoietic stem and progenitor cells (HSPCs). Although nonhuman primates (NHPs) serve as indispensable models for stud…
View article: A thymus-independent artificial organoid system supports complete thymopoiesis from Rhesus macaque-derived hematopoietic stem and progenitor cells
A thymus-independent artificial organoid system supports complete thymopoiesis from Rhesus macaque-derived hematopoietic stem and progenitor cells Open
Thymic output has been extensively studied. While advanced ex-vivo T cell generative approaches exist for mouse and human models, such advancements for nonhuman primate model are lacking. We report the establishment of a rhesus macaque-spe…
View article: Oncologic outcomes and predictors of recurrence following minimally invasive and open surgery for thymoma
Oncologic outcomes and predictors of recurrence following minimally invasive and open surgery for thymoma Open
Our data demonstrates that both OT and MIS have excellent outcomes with respect to OS for early-stage thymoma. For low surgical risk patients with small anterior mediastinal masses which are suspicious for thymoma, removal using an MIS app…
View article: Bridging cell morphological behaviors and molecular dynamics in multi-modal spatial omics with MorphLink
Bridging cell morphological behaviors and molecular dynamics in multi-modal spatial omics with MorphLink Open
Multi-modal spatial omics data are invaluable for exploring complex cellular behaviors in diseases from both morphological and molecular perspectives. Current analytical methods primarily focus on clustering and classification, and do not …
View article: Analytical Comparison of Commonly Used Laboratory-Developed Tests for the Assessment of Ki-67 in Breast Carcinoma With a Food and Drug Administration–Approved Benchmark
Analytical Comparison of Commonly Used Laboratory-Developed Tests for the Assessment of Ki-67 in Breast Carcinoma With a Food and Drug Administration–Approved Benchmark Open
Ki-67 immunohistochemistry (IHC), a commonly used assay for breast cancer risk prognostication, has significant interlaboratory heterogeneity. This study assessed the impact of antibody clones by comparing the Ki-67 IHC MIB-1 pharmDx assay…
View article: Augmented reality microscopy to bridge trust between AI and pathologists
Augmented reality microscopy to bridge trust between AI and pathologists Open
Diagnostic certainty is the cornerstone of modern medicine and critical for maximal treatment benefit. When evaluating biomarker expression by immunohistochemistry (IHC), however, pathologists are hindered by complex scoring methodologies,…
View article: Malignant phyllodes tumours of the breast: the case for revising <scp>WHO’</scp>s ‘full house’ diagnostic criteria
Malignant phyllodes tumours of the breast: the case for revising <span>WHO’</span>s ‘full house’ diagnostic criteria Open
Phyllodes tumours (PTs) of the breast present diagnostic challenges due to their complex histological features and potential for malignant behaviour. The World Health Organisation (WHO) classification requires the presence of five adverse …
View article: Classification of Fibroepithelial Lesions of the Breast in Core Needle Biopsy With Implications for Further Management
Classification of Fibroepithelial Lesions of the Breast in Core Needle Biopsy With Implications for Further Management Open
View article: Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ Open
Importance Active monitoring for low-risk ductal carcinoma in situ (DCIS) of the breast has been proposed as an alternative to guideline-concordant care, but the safety of this approach is unknown. Objective To compare rates of invasive ca…
View article: Cardiovascular disease in thymic cancer patients
Cardiovascular disease in thymic cancer patients Open
Introduction Cancer patients may have increased risk for adverse cardiac events, but our understanding of cardiovascular risk in thymic cancer patients is not clear. We sought to characterize baseline cardiometabolic risk factors before th…
View article: MorphLink: Bridging Cell Morphological Behaviors and Molecular Dynamics in Multi-modal Spatial Omics
MorphLink: Bridging Cell Morphological Behaviors and Molecular Dynamics in Multi-modal Spatial Omics Open
Multi-modal spatial omics data are invaluable for exploring complex cellular behaviors in diseases from both morphological and molecular perspectives. Current analytical methods primarily focus on clustering and classification, and do not …
View article: Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival
Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival Open
The 21-gene RS is prognostic for distant recurrence and overall survival in early breast cancer. A model integrating the 21-gene RS and clinicopathologic factors improved estimates of distant recurrence risk compared with either used indiv…
View article: Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.
Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival. Open
BACKGROUND: The 21-gene recurrence score (RS) assay (Oncotype DX) is used to guide adjuvant chemotherapy use for patients with hormone receptor-positive, HER2 (human epidermal growth factor receptor 2)-negative, axillary node-negative brea…
View article: A prognostic and predictive computational pathology immune signature for ductal carcinoma in situ: retrospective results from a cohort within the UK/ANZ DCIS trial
A prognostic and predictive computational pathology immune signature for ductal carcinoma in situ: retrospective results from a cohort within the UK/ANZ DCIS trial Open
National Cancer Institute under award number U01CA269181, Cancer Research UK (C569/A12061; C569/A16891), and the Breast Cancer Research Foundation, New York (NY, USA).
View article: Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy Open
Importance The absolute benefit of chemotherapy for all patients with stage I triple-negative breast cancer (TNBC) is unclear, and biomarkers are not currently available for selecting patients with an excellent outcome for whom neoadjuvant…
View article: 356 The Effect of Regional Anesthesia on Breast Cancer Recurrence
356 The Effect of Regional Anesthesia on Breast Cancer Recurrence Open
OBJECTIVES/GOALS: To determine the impact of regional anesthesia (RA) on rates of breast cancer recurrence, breast cancer specific mortality, post mastectomy pain syndrome, and chronic opioid use among patients who received regional anesth…
View article: Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study
Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study Open
View article: Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer
Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer Open
Recent advances in the field of immuno‐oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in predicting disease prognosis and treatment response…
View article: AB018. Local recurrence of thymoma following minimally invasive resection: a retrospective case series
AB018. Local recurrence of thymoma following minimally invasive resection: a retrospective case series Open
Background:\nSurgery remains the mainstay treatment for non-metastatic thymic epithelial tumors (TETs) and has traditionally been performed via an open approach. Minimally invasive techniques have gained popularity with the aim of decreasi…
View article: Impact of oncoplasty in increasing breast conservation rates Post neo-adjuvant chemotherapy
Impact of oncoplasty in increasing breast conservation rates Post neo-adjuvant chemotherapy Open
Introduction The essential goal of neoadjuvant chemotherapy (NACT) is to downstage the primary tumor making it amenable for breast conservation surgery (BCS). However, since the safety of this surgery is paramount, post-NACT breast conserv…
View article: Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency
Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency Open
PURPOSE Triple-negative breast cancer (TNBC) is a heterogeneous disease. We previously showed that homologous recombination deficiency (HRD) and the DNA damage immune response (DDIR) signature are prognostic in TNBC. We hypothesized that t…
View article: Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer
Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer Open
The clinical significance of the tumor‐immune interaction in breast cancer is now established, and tumor‐infiltrating lymphocytes (TILs) have emerged as predictive and prognostic biomarkers for patients with triple‐negative (estrogen recep…
View article: Erratum to High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma [Modern Pathology 36(5) (2023) 100154]
Erratum to High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma [Modern Pathology 36(5) (2023) 100154] Open
In the published article "High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma. Mod Pathol 2023;36(5):100154", the…
View article: Supplementary Figure 2 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure 2 from Relationship between Quantitative <i>GRB7</i> RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer Open
PDF file - 72K, Box plots (with center line at the median and box edges at the quartiles) showing the raw distribution of GRB7, ERBB2, KRT19 and PHB expression for the triple negative (TN) subset, hormone receptor negative (HR-), HER2-posi…
View article: Figure S3 from Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer
Figure S3 from Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer Open
Prognostic value of FOXA1-AKT1-ER signature in additional datasets
View article: Data from Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial
Data from Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial Open
Purpose: Clinically validated biomarkers for anti-angiogenesis agents are not available. We have previously reported associations between candidate VEGFA single-nucleotide polymorphisms (SNP) and overall survival (OS) in E210…
View article: Supplementary Data from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer
Supplementary Data from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer Open
Supplementary Data from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer
View article: Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer
Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer Open
Purpose: To perform an exploratory analysis of the relationship between gene expression and recurrence in operable hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–normal breast cancer patients treated…
View article: Supplementary Figure Legend from Telomerase Template Antagonist GRN163L Disrupts Telomere Maintenance, Tumor Growth, and Metastasis of Breast Cancer
Supplementary Figure Legend from Telomerase Template Antagonist GRN163L Disrupts Telomere Maintenance, Tumor Growth, and Metastasis of Breast Cancer Open
Supplementary Figure Legend from Telomerase Template Antagonist GRN163L Disrupts Telomere Maintenance, Tumor Growth, and Metastasis of Breast Cancer
View article: Supplemental Figures and Tables from Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer
Supplemental Figures and Tables from Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer Open
Supplemental Figure 1. Patient inclusion and exclusion criteria. TNBC: triple negative breast cancer; ALC: absolute lymphocyte count; nSES: neighborhood socioeconomic status. Supplemental Figure 2a and 2b. Association between minimum lymph…